Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
42 hedge funds and large institutions have $47.6M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
46% more capital invested
Capital invested by funds: $32.7M → $47.6M (+$14.9M)
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
20% more funds holding
Funds holding: 35 → 42 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.13M |
| 2 |
DAM
DLD Asset Management
New York
|
+$836K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$657K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$628K |
| 5 |
Morgan Stanley
New York
|
+$517K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$676K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$646K |
| 3 |
Renaissance Technologies
New York
|
-$607K |
| 4 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
-$76.9K |
| 5 |
RCWMU
Rothschild & Co Wealth Management (UK)
London,
United Kingdom
|
-$37K |
OPNT Hedge Fund Activity: Q4 2021 in Review
42 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q4 2021, worth a combined $47.6M — up 46% from $32.7M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new OPNT positions and 4 closed out — a net gain of 7 holders — while 11 added to existing stakes and 9 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.13M. The largest seller was EAM Investors, cutting an estimated $676K.
- 42 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q4 2021, up from 35 in Q3 2021.
- Funds reported $47.6M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q4 2021, up 46% quarter-over-quarter.
- 11 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q4 2021 and 4 closed out, a net change of +7 holders.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q4 2021 was Vanguard Group, an estimated $1.13M added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q4 2021 was EAM Investors, an estimated $676K sold.
Based on aggregated 13F filings for Q4 2021.